Whole Health Pharmacy Rheumatology Enrollment Form Fax: 949-340-8008												
		Phone: 9	949-3									
PATIENT INFORMATION PRESCRIBER INFORMATION												
Patient Na Address	me	ing or send patient demographi		Prescriber Name DEA								
Address 2				NPI								
City, State	, Zip	Mobile Phone		Address								
DOB	Last Fo	our of SS Gender _		City, State, Zip Phone Fax								
Language	Preference			Contact Person								
		e fax or email relevant clinical	notes, la	abs, tests, and previous med			horization					
Diagnosis /	ICD 10: gnosis or Years			tment Date:	TB/PPD Test Veight		cm/in					
				currently on therapy? Y N Weightkg/lbs Heightcm/in t terminate current therapy upon start of new prescription? Y N N								
				IPTION INFORMATION		Ĩ						
Туре	Medication	Dose/Strength Dose/Strength	5)	Direction Direction Direct 400mg SQ once. Repea		Quantity	Refill					
TNF Blocker	🗆 Cimzia	 200mg Statter Kit (6x 200mg PrS) 2 x 200mg Prefilled Syringe 		 Inject 200mg SQ once every 2 weeks Inject 400mg SQ once every 4 weeks 		4-week supply	□ 11 □					
	Enbrel	 25mg Prefilled Syringe 50mg/ ml Sureclick Autoinjector 50mg Prefilled Syringe 		 Inject 25mg twice weekly. 72 -96 hours apart Inject 50mg SQ once weekly Other 		4-week supply	□ 1 □ 2 □ 3 □ 4 □ 5 □ 11 □					
	🗆 Humira CF	 40mg/0.4 ml Pen 40mg/0.4 ml Prefilled Syringe Psoriasis Starter Pack Crohn's Starter Pack 		 Inject 40mg SQ every other week Inject 40mg SQ once weekly Inject 80mg SQ on day 1 then inject 40mg on day 8 then inject 40mg every other week thereafter Inject 160mg SQ on day 1 then inject 80mg on day 15 then start maintenance dose 		□ 4-week supply □ 1 starter pack	□ 1 □ 2 □ 3 □ 4 □ 5 □ 11 □					
	Inflectra	□ 100mg/20 ml vial					□ 1 □ 2 □ 3 □ 4 □ 5 □ 11 □					
	Remicade	□ 100mg/ 20 ml vial				□	□ 1 □ 2 □ 3 □ 4 □ 5					
	Simponi	 50mg/0.5ml Prefilled Syringe 50mg/0.5ml Autoinjector 		□ Inject 50mg SQ once a month		□ 4-week supply	□ 11 □ □ 1 □ 2 □ 3 □ 4 □ 5 □ 11 □					
	 Simponi Aria 	50mg/4 ml single-use vial		 2mg/kg IV over 30 minutes at weeks 0 and 4, then every 8 weeks thereafter 2mg/kg over 30 minutes every 8 weeks 		4-week supply	□ 1 □ 2 □ 3 □ 4 □ 5 □ 11 □					
IL-6	Actemra	□ 162mg/0.9 ml PFS		 Inject 1 syringe SQ once weekly Inject 1 Syringe SQ every other week 		4-week supply	□ 1 □ 2 □ 3 □ 4 □ 5 □ 11 □					
Antagonist		IV infusion Bomg/4 ml (20mg/ml) 200mg/10ml (20mg/ml) 400mg/20ml (20mg/ml) in a single dose vial for further dilution prior to IV infusion				0 1 0 2 0 3 0 4 0 5 0 11 0						
	🗆 Kevzara	□ 150mg prefilled Syringe		□ 150mg SQ once every 2 weeks		□ 4-week	□ 1 □ 2 □ 3 □ 4 □ 5					
		200mg prefilled Syringe 150mg/ml single use Sensoready pen		 200mg SQ once every 2 weeks 150mg SQ at weeks 0,1,2,3, & 4 and every 4 		supply						
IL-17A Antagonist	Cosentyx	 Isomg/mi single use Sensoready pen Isomg/mi single-use prefilled syringe 300mg lyophilized powder in a single use vial for reconstitution 		 Doing SQ at weeks 0,1,2,3, 6 weeks thereafter 150mg SQ every 4 weeks 300mg SQ every 4 weeks 		□ 4-week supply						
	🗆 Taltz	 Bomg Auto-Injector Starter Kit (3 pens) Bomg Auto-Injector (2 pens) Bomg Auto-Injector (1 pen) Bomg Prefilled Syringe (1 syringe) 		 160mg SQ on day 1, then followed by 80mg every 4 weeks thereafter 80mg SQ every 4 weeks 		4-week supply	□ 1 □ 2 □ 3 □ 4 □ 5 □ 11 □					
IL-12,23 Antagonist	🗆 Stelara	45 mg Prefilled Syringe 90 mg Prefilled Syringe		□ Inject SQ weeks 0,4, and every 12 weeks thereafter □ Inject 1 syringe SQ every 12 weeks		4-week supply	□ 1 □ 2 □ 3 □ 4 □ 5 □ 11 □					
IL-23 Antagonist	Tremfya	□ 100 mg/ml Prefilled Syringe □ 100 mg/ml Pen		 Inject 100mg SQ at weeks 0 and 4 (starter) Inject 100mg SQ every 8 weeks 		4-week supply	□ 1 □ 2 □ 3 □ 4 □ 5 □ 11 □					
T cell Co- stimulation Modulator	🗆 Orencia	 125 mg/ml Prefilled Syringe 125 mg/ml Clickjet Autoinjector (250mg/ 15ml vial (IV only) 	(pen)	 Inject 100mg SQ every 6 weekly Inject 125 mg SQ once weekly Infusemg IV every 4 weekly 	/	□ 4-week supply	0 1 0 2 0 3 0 4 0 5 0 11 0					
Shin to:	Patient Office	□ Other		Date:	Need by Date							
			rized agent to		/	d to sign any pecce	sary forms on my behalf as					
*Prescriber Authorization: I authorize this pharmacy and its representatives to act as my authorized agent to secure coverage and initiate the insurance prior authorization process for my patient(s) and to sign any necessary forms on my behalf as my authorized agent, including the receipt of any required prior authorizations forms and the receipt and submission of patient tab values and other patient data, in the event that this pharmacy determines that it is unable to fulfill this prescription, I further authorize the pharmacy to forward this information and any related materials related to coverage of the product to another pharmacy of the patient's choice or in the patient's insurer's provider network.												

 $\hfill\square$ Product Substitution permitted $\hfill\square$ Dispense as Written

Prescriber's Signature:

_ Date: _

CONFIDENTIALITY STATEMENT: This communication is intended for use of the individual or entity to which it is addressed and may contain information that is privileged, confidential, and exempt from disclosure under applicable law If the reader of this communication is not the intended recipient or the employee or agent responsible for delivery of the communication, you are hereby notified that any dissemination distribution, or copying of the communication is strictly prohibited. If you have received this communication in error, please notify us immediately by telephone. Whole Health Pharmacy • 1415 N Broadway, Santa Ana, CA 92706 <u>WWW.MYWHRX.com</u> V5.21

W	Whole Health Pharmacy	Rheu Fax: 949 Phone: 9)-340-8	5-0788		ent Fo	orm		
Patient Name Address City, State, Zip Home Phone DOB	CORMATION the following or send path Mobile P Last Four of SS erence	hone Gender		PRESCRIBER INFORMATION Prescriber Name DEA NPI Address City, State, Zip Phone Fax Contact Person					
Clinical Diagno Diagnosis / ICD 10:	osis: please fax or email		otes, labs, rior Treatm	tests, and previous med ent Date:	lical history to exp TB/PPD Test 🗆 Ye		thorization		
	s or Years with Disease previously treated? _Y _	N W His	Vill patient story of Fra			<u> </u>	leightcm/in N		
_				ION INFORMATION					
Type CD 20-directed cytolytic antibody	Medication Dose/Strength Rituxan I0mg /ml 		gth	Directions		Quantity	Refill □ 1 □ 2 □ 3 □ 4 □ 5 □ 11 □		
PDE 4 inhibitor		Otezla Otezla		 Take as directed Take 1 tablet PO twice daily 		 1 pack 60 tablets 			
JAK inhibitor		□ 2 mg tablets		 Take 2mg PO once daily Take 15mg PO once daily 		 30 tablets 30 tablets 			
	Rinvoq Xeljanz	15 mg tablets		Take 5mg PO twice daily					
		5mg tablets				60 tablets			
	Xeljanz XR I1mg tablets			□ Take 15mg PO once daily		30 tablets	□ 1 □ 2 □ 3 □ 4 □ 5 □ 11 □		
rhPTH (1-34)	 Forteo BD Ultra Fine Pen Needles 	□ 600 mcg/2.4 ml P Syringe		Inject 20 mcg SQ as directed once daily		4-week supply	□ 1 □ 2 □ 3 □ 4 □ 5 □ 11 □		
PTH1R agonist	 Tymlos BD Ultra Fine Pen Needles 	B0mcg Prefilled Syringe		Inject 80 mcg SQ once daily		4-week supply	□ 1 □ 2 □ 3 □ 4 □ 5 □ 11 □		
RANK L inhibitor	Prolia	60mg Prefilled Syn	-	Inject 60mg SQ once every 6 months			□ 1 □ 2 □ 3 □ 4 □ 5 □ 11 □		
BLyS inhibitor	 Benlysta 120 mg/5ml single-dose vial 400mg/20ml single-dose vial 200mg/ml single-dose prefilled autoinjector 200mg/ml single-dose prefilled autoinjector prefilled syringe 		 10mg/kg IV at 2-week intervals for the first 3 doses and at 4-week intervals thereafter 200mg SQ once weekly 		□ 4-week supply	0 1 0 2 0 3 0 4 0 5 0 11 0			
Pegylated uric acid specific enzyme	Krystexxa Smg/ml vial			 Bmg given as an intravenous infusion every 2 week for chronic Gout 		□	□ 1 □ 2 □ 3 □ 4 □ 5 □ 11 □		
Bisphosphonate	 Zoledronic Acid 	 5mg in a 100 ml r infuse solution 	ready-to-	□ Infuse 5mg/100 ml IV ove	er 30 minutes	□	□ 1 □ 2 □ 3 □ 4 □ 5 □ 11 □		
Corticosteroid	Rayos Img tablets 2mg tablets 3mg tablets			· · · · · · · · · · · · · · · · · · ·		 30 tablets 60 tablets 90 tablets 	□ 1 □ 2 □ 3 □ 4 □ 5 □ 11 □		
Other	□	□		□		□	□ 1 □ 2 □ 3 □ 4 □ 5 □ 11 □		
Chin tay D. I				Data	Needly D.:				
Ship to: Patient Office Ofter Office Ofter Date: Need by Date Prescriber Authorization: I authorize this pharmacy and its representatives to act as my authorized agent, including the receipt of any required prior authorizations forms and the receipt and submission of patient tab values and other patient data, in the event that this pharmacy determines that it is unable to fulfill this prescription, I further authorize the pharmacy to forward this information and any related materials related to coverage of the product to another pharmacy of the patient's choice or in the patient's insurer's provider network. Product Substitution permitted Dispense as Written									
Prescriber's Signature:									
agent responsible for delivery of		issemination distribution, or copying of th		trictly prohibited. If you have received this communicat	uon in error, piease notity us immediatel	y uy telephone.			

 Whole Health Pharmacy · 1415 N Broadway, Santa Ana, CA 92706
 www.MYWHRX.com
 V5.21